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Aims: In breast cancer survivors, we aimed to describe the frequency of hot flashes and night 
sweats, frequency and type of treatment, and the association of hot flashes and use of calcium 
supplements.
Methods: Charts of breast cancer survivors were reviewed for information about hot flashes, 
treatment for hot flashes, and calcium supplementation. Associations between variables were 
explored using the Chi-square test and Fisher’s Exact test.
Results: Eighty-six charts were reviewed. Mean age of the women was 58 years and 79% were 
postmenopausal. Forty-two (49%) of women had hot flashes and 18 (21%) had night sweats. 
Thirty-one (36%) were treated for hot flashes. Treatment included selective serotonin reuptake 
inhibitors/serotonin-norepinephrine reuptake inhibitors (n = 19), clonidine (n = 7), Bellergal-S® 
(n = 8), sleep-aid (n = 7), and other (n = 5). Calcium supplementation was recorded in 31%. Of 
women with hot flashes, 44% took calcium supplements; of women without hot flashes, 18% 
took calcium supplements (Chi-square P = 0.02).
Conclusion: Hot flashes were recorded in 49% of this group of primarily postmenopausal breast 
cancer survivors. Women with hot flashes were more likely to be taking calcium   supplements. 
Further exploration of the association between hot flashes and calcium supplementation is 
warranted.
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Introduction
Hot flashes are bothersome and sometimes life-disrupting in breast cancer survivors. 
Estrogen-based therapies decrease hot flashes by up to 90%, but their use is generally 
discouraged in breast cancer survivors and in women with an increased risk of breast 
cancer.1–3
Several hormonal and nonhormonal therapies are claimed to alleviate hot flashes. 
These include hormonal agents, such as progestational agents, complementary 
and alternative therapies and supplements, and pharmacologic agents. Hormonal 
therapies seem to be most effective, but women at risk for or who have survived 
breast cancer may carry an increased risk of new or relapsed cancer.4 As such, 
studies have aimed to find nonhormonal agents that can decrease this bothersome 
symptom. Many therapies have been studied, but none seem to be as effective 
as hormonal therapies.5 Other commonly prescribed nonhormonal treatments for 
hot flashes are well described in a recent review,6 and include selective serotonin 
reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), 
clonidine, gabapentin, and others.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Many women take prescription and over-the-counter medica-
tion for treatment of hot flashes. There is sparse information about 
what women are actually taking. In a population of breast cancer 
patients, we aimed to describe the frequency of hot flashes and night 
sweats, list what   treatments were employed, and explore the possible 
association of hot flashes and use of calcium supplements.
Methods
We retrospectively reviewed clinic charts of a randomly 
selected sample of women with breast cancer treated at a 
single institution. Cases were randomly selected for inclusion 
by arranging all breast cancer cases in alphabetical order and 
then choosing every fourth chart for review. The study was 
approved by the Institutional Review Board at Wake Forest 
University School of Medicine.
Information gathered included the following:   demographic 
information including age at diagnosis and race; adjuvant 
  hormonal therapy use for breast cancer, defined as any record 
in the chart for prescription of tamoxifen or an aromatase 
inhibitor; menopausal status as recorded in clinician notes; 
presence or absence of hot flashes and/or night sweats as 
recorded in the chart; prescribed treatment for hot flashes as 
indicated in the clinical records; and any record of calcium 
supplementation in the medication list, although the exact 
amount of calcium per day and additional use of vitamin D 
was not available in most charts.
Descriptive statistics were used to describe variables. To 
explore the associations between variables, the Chi-square 
test and Fisher’s Exact tests were used for variables with 
larger and smaller sample sizes, respectively.
Results
There were 86 charts reviewed (Table 1). Menopausal status 
was post- in 79%, peri- in 10%, and pre- in 11%. A record 
of hot flashes was found in 42 (49%) charts and a record of 
  night-time hot flashes was found in 18 (21% of the total and 
43% of those with hot flashes) charts (Table 2). Hot flashes 
were reported as   life-disrupting in 17% of charts reviewed.
There was no statistically significant association between 
presence of hot flashes and antihormonal therapy; 42% of 
women not taking antihormonal therapy reported hot flashes 
versus 59% on antihormonal therapy (P = 0.13).
Treatment for hot flashes was recorded in 31 (36%) of the 
86 charts. Treatments for hot flashes included SSRIs/SNRIs 
(n = 19), clonidine (n = 7), Bellergal-S® (n = 8), sleep-aid 
(n = 7), and others (n = 5).
Calcium supplementation was recorded in 31% of 
records. Interestingly, we found an association between hot 
flashes and calcium supplementation. Of women with hot 
flashes, 44% took calcium supplements and 56% did not; of 
women without hot flashes, 18% took calcium supplements 
and 82% did not (Chi-square P = 0.02) (Table 3).
Discussion
Hot flashes were recorded in half of this group of primarily 
postmenopausal breast cancer survivors. Among women with 
hot flashes, almost half also complained of night sweats. 
These figures are similar to what has been reported in a 
Table 1 Patient characteristics
Age at diagnosis, mean (range) 58 (29–92)
Menopausal status, n (%)
  Pre 9 (11)
  Peri 8 (10)
  Post  65 (79)
race, n (%)
  White 62 (84)
  nonwhite 12 (16)
Height, median (range) 63.5 (58–71) cm
Weight, median (range) 72.6 (45.4–117.9) kg
Tumor size, n (%)
  T1 35 (48)
  T2 30 (42)
  T3 5 (7)
  T4b 2 (3)
nodal status, n (%)
  negative 39 (54)
  Positive 31 (43)
  Unknown 2 (3)
  Metastatic disease, n 8
er status
  Positive 53 (80)
  negative 13 (20)
Pr status
  Positive 42 (68)
  negative 20 (32)
Her2 status
  Positive 22 (51)
  negative 21 (49)
Table 2 Finding complaint of hot flashes, night sweats, and indi-
cation that hot flashes were life-disrupting in the medical record
n (%)
Hot flashes 42 (48)
night sweats 18 (21)
Life-disrupting hot flashes 14 (17)International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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review of the world literature on prevalence of hot flashes 
and night sweats.7
We found no relationship between use of antihormonal 
therapy and occurrence of hot flashes. In contrast, clinical 
trials and other studies find that menopausal symptoms are 
more common in breast cancer patients versus controls 
and in patients taking antihormonal therapy versus not.7–12 
There are several possible explanations for the lack of 
an effect of antihormonal therapy on occurrence of hot 
flashes in our analysis. First, there may have been a lack 
of recorded information about hot flashes in the medical 
records, but at this particular institution, there were ongo-
ing studies for women with hot flashes and inquiry about 
the symptom was common. Second, the study population, 
although randomly selected from an existing group, may 
not be representative of the group or of the population of 
breast cancer survivors as a whole. Third, the study may 
have lacked the power to find a difference. Alternatively, 
the finding may be real in this population of primarily 
postmenopausal women, whose hot flash level may not have 
been as significantly affected by the addition of adjuvant 
hormonal therapy.
In this sample of breast cancer survivors, record of a 
treatment for hot flashes was found in 36% of charts. This 
is lower than found in a survey of a family practice, where 
almost 70% of postmenopausal women with moderate-to-
severe hot flashes said they would want an intervention, with 
a desired hot flash reduction of at least 50%.13
Breast cancer survivors in this study were taking a vari-
ety of treatments to manage symptoms of hot flashes. These 
included SSRIs/SNRIs, clonidine, Bellergal-S, sleep-aid, and 
others. None of the charts reviewed recorded use of estrogen or 
herbal supplements to manage hot flashes. This is in line with 
therapies that have been proven helpful and safe in managing 
hot flashes in breast cancer survivors.6 In a systematic review 
and meta-analysis of data on nonhormonal therapies for 
menopausal hot flashes, compared with   placebo, the number 
of daily hot flashes decreased with SSRIs or SNRIs (mean dif-
ference −1.13; 95% confidence interval [CI] −1.70 to −0.57), 
clonidine (−0.95; 95% CI −1.44 to −0.47), and gabapentin 
(−2.05; 95% CI −2.80 to −1.30).5 This chart review took place 
in 2003, before gabapentin and pregabalin had been shown to 
be helpful for treatment of hot flashes.14–16 In a case-control 
study of 73 breast cancer survivors, 29% reported use of 
nonestrogen therapy specifically for   treatment of menopausal 
symptoms.12 In their study, which was   published perhaps 
before widespread acceptance of the value of SSRIs/SNRIs 
for alleviation of hot flashes, the most commonly reported 
nonestrogen treatments were   deliberate increase in either 
dietary or   supplemental soy   products, vitamin E, other herbal 
preparations, clonidine, vitamin B6, and other miscellaneous 
therapies.   Antidepressants, including tricyclic antidepressants 
(used in 2/73 cases) and   venlafaxine (used in 1/73 cases), were 
among the miscellaneous therapies.
Having observed reports that calcium might alleviate 
symptoms of premenstrual syndrome,17,18 we were interested 
to explore the possibility that calcium supplements might 
alleviate hot flashes. Interestingly, we found an association 
between calcium supplementation and hot flashes, but it was 
not in the direction that we had hypothesized. Women whose 
records indicated use of calcium supplements were more likely 
to report hot flashes than those not using calcium. One possible 
explanation for this could be as simple as the fact that women 
with lower estrogen levels, and thereby more hot flashes, have 
lower bone mass and are more frequently told to take calcium 
supplements. In other words, we may simply find more hot 
flashes in women who take calcium because of low estrogen 
levels. Another potential explanation is that some women were 
taking calcium supplements to treat hot flashes, but we did not 
find this was the case from the records reviewed. However, 
this was a retrospective study, and we realize that we may not 
be able to detect when a patient independently decided to take 
calcium supplements to treat hot flashes and, if this particular 
therapeutic strategy was of low efficacy, we would detect a 
higher level of hot flashes in these women.
Alternatively, calcium intake may induce   production of 
hormones that increase hot flashes. A plausible   endocrinologic 
explanation for calcium’s relationship with hot flashes is 
through calcitonin gene-related peptide (CGRP). Calcium 
stimulates secretion of two peptides, ie, calcitonin, a hormone 
that functions to reduce blood calcium levels by increasing 
renal calcium excretion and decreasing release of calcium 
from bone, and CGRP, a neuropeptide that may be important 
in vasomotor-related symptoms. CGRP is a potent   vasodilator 
neuropeptide and has been shown to be closely related to 
the occurrence of menopausal hot flashes.19–22 In addition, 
CGRP is high in postmenopausal women with hot flashes 
Table 3 Association between hot flashes and calcium supplementation 
Calcium supplement
No Yes
Hot flashes
  no 31 7 38
  Yes 19 15 34
50 22
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and decreases after successful treatment.23,24 Although a 
causal explanation for the increased reports of hot flashes in 
women also taking calcium cannot be made from this study, 
further exploration of the association between hot flashes 
and calcium supplementation is warranted.
Conclusion
In summary, complaints of hot flashes were found in the 
records of approximately half of these breast cancer   survivors 
and were life-disrupting in 17%. Half of those with hot 
flashes also complained of night sweats. A variety of medi-
cations were used for hot flashes, including those that were 
considered effective at the time. Calcium supplementation 
does not appear to alleviate hot flashes. In fact, we found 
an association between calcium supplementation and hot 
flashes, such that women taking calcium supplements were 
more likely to report hot flashes. Because the combination 
of calcium and vitamin D is recommended for good bone 
health, the relationship of this combined supplementation 
and hot flashes warrants exploration.
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